The T cell druggable genome – a new target space for cancer drugs

Mainz, Germany, September 6, 2012 – The emerging era of individualized cancer immunotherapy is dramatically changing the target landscape by adding targets that can be recognized by antibodies and T cells, thus significantly increasing the number of druggable tumor targets. In a recent article in the European Pharmaceutical Review, TRON scientists describe a process to generate patient-specific custom-made therapeutic vaccines to provide patients with a more efficacious and less toxic treatment. Currently the targets in a patient tumor are addressed by no more than seven small molecule and monoclonal antibody therapies, while the potential druggable therapeutic target space for T cell vaccination from both mutated and non-mutated antigens is more than 10 times larger. The authors argue that on-demand production of tailored vaccines open the door to an entirely new source of druggable therapeutic targets, the abundant space of individual cancer mutations.

Reference:

Diekmann, J., Löwer, M., Castle, J.C., Kreiter, S., Türeci, Ö., Sahin, U. (2012) The T Cell Druggable Genome. European Pharmaceutical Review. Vol. 17. Issue 4. 2012.
Link;